XML 33 R24.htm IDEA: XBRL DOCUMENT v3.23.3

Equity Method Investment (Tables)

9 Months Ended

Sep. 30, 2023

Equity Method Investment

Schedule of financial information of Angel Pharmaceuticals Co.

​

​	​	​	​	​	​	​
​	​	​	As of	​	​	As of
Balance Sheet Data		September 30, 2023		​	December 31, 2022
​		(in thousands)
Current assets	​	$	18,765	​	$	29,062
Non-current assets	​		1,329	​		1,652
Current liabilities	​		1,613	​		6,293
Non-current liabilities	​		686	​		985
Stockholders' equity	​	​	17,795	​	​	23,436

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Nine Months Ended

​

​

September 30,

​

September 30,

Statement of Operations Data

2023

​

2022

​

2023

​

2022

​

(in thousands)

Revenue

​

$

—

​

$

—

​

$

—

​

$

—

Gross Profit

​

—

​

—

​

—

​

—

Net loss

​

​

(1,016)

​

​

(3,204)

​

​

(4,565)

​

​

(6,402)

Share of loss from investments accounted for using the equity method

​

(865)

​

(2,730)

​

(3,880)

​

(5,367)

​

X

- References

No definition available.

+ Details

Name:	us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

+ Details

Name:	us-gaap_EquityMethodInvestmentsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration